A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell non-Hodgkin lymphoma (NHL) or bulky stage II lymphoma

Neal P. Christiansen,Raul R. Mena,Yudhishtra Markan,Lalita Pandit

A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell non-Hodgkin lymphoma (NHL) or bulky stage II lymphoma

2007

Neal P. Christiansen
Raul R. Mena
Yudhishtra Markan
Lalita Pandit

8071 Background: The decision to treat indolent B-cell NHL is often based on progressive disease, worsening symptoms, and increasing hematological variations. When treatment is indicated, these lym...

Keywords:

Oncology
Pentostatin
Stage II Lymphoma
Internal medicine
Medicine
B-Cell Non-Hodgkin Lymphoma
Pathology
Progressive disease
open label study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations